SCHEMBL6634845

SCHEMBL6634845

CNc1cnccc1-c1ccccc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 5/20 0.50
CYP3A4 P08684 4/20 0.50
CYP2D6 P10635 4/20 0.50
AOC1 P19801 2/20 0.43
AOC3 Q16853 2/20 0.43
LIMK1 P53667 1/20 0.43
CYP2C19 P33261 4/20 0.42
ALOX15 P16050 2/20 0.42
HSD17B10 Q99714 2/20 0.42
CLK4 Q9HAZ1 1/20 0.42
KDM4C Q9H3R0 1/20 0.42
GPBAR1 Q8TDU6 8/20 0.42
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPK1 P28482 1/20 0.40
TSHR P16473 1/20 0.40
LRRK2 Q5S007 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6866715 0.86 CYP1A2 (0.54) CYP1A2CYP3A4CYP2D6AOC1AOC3
SCHEMBL12097609 0.81 LIMK1 (0.43) CYP1A2CYP3A4CYP2D6LIMK1CYP2C19
SCHEMBL6636940 0.81 LIMK1 (0.46) CYP3A4AOC1AOC3LIMK1KDM4C
SCHEMBL27958536 0.81 GSK3A (0.44) AOC1AOC3KDM4CGPBAR1MAOA
SCHEMBL19721401 0.81 GRM4 (0.49) CYP1A2CYP3A4CYP2D6LIMK1GPBAR1
SCHEMBL16628650 0.80 GPBAR1 (0.47) CYP1A2CYP3A4CYP2D6CYP2C19KDM4C
Hydrochloric Acid SCHEMBL6635057 0.79 LIMK1 (0.48) CYP3A4AOC1AOC3LIMK1KDM4C
Hydrochloric Acid SCHEMBL27958789 0.79 AOC1 (0.44) AOC1AOC3KDM4CGPBAR1MAOA
SCHEMBL6873187 0.78 CYP1A2 (0.47) CYP1A2CYP3A4CYP2D6CYP2C19ALOX15
SCHEMBL12097338 0.78 CYP2A6 (0.51) CYP1A2CYP3A4CYP2D6AOC1AOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2681194-B1 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS HOFFMANN LA ROCHE (CH) 2015-04-15 EP claimed
US-10385022-B2 3-amino-pyridines as GPBAR1 agonists HOFFMANN-LA ROCHE INC. (US) 2019-08-20 US disclosed
CN-103415507-B As the 3-amino-pyridine class of GPBAR1 agonist HOFFMAN-LA ROCHE LTD. (CH) 2016-03-02 CN disclosed
US-20150152058-A1 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS HOFFMANN-LA ROCHE INC. 2015-06-04 US disclosed
EP-2681194-B1 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS HOFFMANN LA ROCHE (CH) 2015-04-15 EP disclosed
US-8987307-B2 3-amino-pyridines as GPBAR1 agonists HOFFMANN-LA ROCHE INC. (US) 2015-03-24 US disclosed
EP-2681194-A1 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2014-01-08 EP disclosed
US-20120232051-A1 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS HOFFMANN-LA ROCHE INC. 2012-09-13 US disclosed
WO-2012117000-A1 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2012-09-07 WO disclosed
EP-1035115-B1 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists HOFFMANN LA ROCHE (CH) 2004-09-29 EP disclosed
EP-1394150-A1 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists F. HOFFMANN-LA ROCHE AG (CH) 2004-03-03 EP disclosed
US-6479483-B2 3,4,6-SUBSTITUTED PYRIDINE DERIVATIVES USEFUL FOR TREATING DEPRESSION AND PAIN, RESULTING FROM INFLAMMATORY CONDITIONS, SUCH AS MIGRAINE, RHEUMATOID ARTHRITIS, ASTHMA AND INFLAMATORY BOWEL DISEASE; NK1 RECEPTOR ANTAGONIST HOFFMANN-LA ROCHE INC. 2002-11-12 US disclosed
US-20020091265-A1 4-phenyl-pyridine derivatives BOS MICHAEL (CA) 2002-07-11 US disclosed
US-6297375-B1 4-phenyl-pyridine derivatives HOFFMANN-LA ROCHE INC. 2001-10-02 US disclosed
EP-1035115-A1 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists F. HOFFMANN-LA ROCHE AG (CH) 2000-09-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10385022-B2 3-amino-pyridines as GPBAR1 agonists GPBAR1, ADRA1B, GPR119 CYP1A2 419/4885CYP3A4 1054/4885CYP2D6 664/4885
US-20120232051-A1 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS GPBAR1, ADRA1B, GPR119 CYP1A2 419/4885CYP3A4 1054/4885CYP2D6 664/4885
US-20150152058-A1 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS GPBAR1, ADRA1B, GPR119 CYP1A2 419/4885CYP3A4 1054/4885CYP2D6 664/4885
US-20020091265-A1 4-phenyl-pyridine derivatives CBR1, CBR3, HCCS CYP1A2 1297/4885CYP3A4 908/4885CYP2D6 600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.